Skip to main content

Research Repository

Advanced Search

All Outputs (6)

Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach? (2024)
Journal Article
Tripp, R. A., Cui, H., & Elkord, E. (2024). Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?. Vaccines, 12(12), 1306. https://doi.org/10.3390/vaccines12121306

The discovery of immune checkpoints (ICs) has pushed cancer treatment into the next era. As an emerging immune checkpoint, the TIGIT/CD155 axis inhibits the cytotoxicity of T and NK cells through multiple pathways. Immune checkpoint inhibitors (ICIs)... Read More about Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?.

What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes? (2024)
Journal Article
Meyiah, A., & Elkord, E. (in press). What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes?. Expert Review of Clinical Immunology, 1-7. https://doi.org/10.1080/1744666X.2024.2334258

Forkhead box P3 (FoxP3) transcription factor plays critical roles in controlling immune responses and cancer progression in different cancers. FoxP3 expression within the tumor microenvironment (TME) may influence clinical outcomes negatively or posi... Read More about What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes?.

The integrative multi-omics approach identifies the novel competing endogenous RNA (ceRNA) network in colorectal cancer (2023)
Journal Article
Mahmoodi Chalbatani, G., Gharagouzloo, E., Malekraeisi, M. A., Azizi, P., Ebrahimi, A., Hamblin, M. R., …Panahi, B. (in press). The integrative multi-omics approach identifies the novel competing endogenous RNA (ceRNA) network in colorectal cancer. Scientific Reports, 13(1), 19454. https://doi.org/10.1038/s41598-023-46620-z

Circular RNAs (circRNA) are known to function as competing endogenous RNA (ceRNA) in various cancers by regulating microRNAs (miRNA). However, in colorectal cancer (CRC), the precise pathological role of circ000240/miRNA/mRNA remains indeterminate. T... Read More about The integrative multi-omics approach identifies the novel competing endogenous RNA (ceRNA) network in colorectal cancer.

Structure-based small inhibitors search combined with molecular dynamics driven energies for human programmed cell death-1 (PD-1) protein (2023)
Journal Article
Waqas, M., Halim, S. A., Alsalman, A., Khan, A., Elkord, E., & Al-Harrasi, A. (2023). Structure-based small inhibitors search combined with molecular dynamics driven energies for human programmed cell death-1 (PD-1) protein. Journal of Biomolecular Structure and Dynamics, 41(24), 14771-14785. https://doi.org/10.1080/07391102.2023.2188958

Human immune system is specialized in distinguishing normal cells from foreign particles mainly through proteins expressed on immune cells called ‘checkpoints’. Immune checkpoints work as a switch to activate and deactivate immune responses. T cells... Read More about Structure-based small inhibitors search combined with molecular dynamics driven energies for human programmed cell death-1 (PD-1) protein.

Correlations between Circulating and Tumor-Infiltrating CD4+ T Cell Subsets with Immune Checkpoints in Colorectal Cancer (2022)
Journal Article
Al-Mterin, M. A., Murshed, K., & Elkord, E. (2022). Correlations between Circulating and Tumor-Infiltrating CD4+ T Cell Subsets with Immune Checkpoints in Colorectal Cancer. Vaccines, 10(4), 538. https://doi.org/10.3390/vaccines10040538

T regulatory cells (Tregs) play different roles in the regulation of anti-tumor immunity in colorectal cancer (CRC), depending on the presence of different Treg subsets. We investigated correlations between different CD4+ Treg/T cell subsets in CRC p... Read More about Correlations between Circulating and Tumor-Infiltrating CD4+ T Cell Subsets with Immune Checkpoints in Colorectal Cancer.